促肾上腺皮质激素凝胶在难治性皮肌炎和多发性肌炎中的疗效与安全性
这项开放标签临床试验在两家中心纳入11例难治性成人多发性肌炎(PM)和皮肌炎(DM)患者,给予repository corticotropin injection(RCI)80单位皮下注射、每周两次、共24周。10例完成研究,7例(70%)在中位8周达到主要疗效终点,泼尼松剂量从基线18.5(15.7)mg显著降至结束时2.3(3.2)mg(P<0.01),RCI被认为安全可耐受。
要点
- 10例完成研究中7例(70%)在中位8周达到国际肌炎评估与临床研究定义的改善。
- 泼尼松剂量从基线18.5(15.7)mg降至结束时2.3(3.2)mg(P<0.01)。
- 第24周多数核心组指标改善,肌力改善>10%,医生总体评估改善>40%。
核心结论
- RCI治疗对70%的难治性成人肌炎患者有效,安全可耐受,并使糖皮质激素和传统免疫抑制剂难治患者的激素剂量减少。
研究设计与样本
- 开放标签临床试验,由两家中心纳入11例难治性成人PM和DM患者,所有患者接受RCI 80单位皮下注射、每周两次、共24周,10例完成研究。
主要发现
- 11例入组受试者中10例(6例DM、4例PM)完成研究,10例中7例在中位8周达到主要疗效终点。
- 泼尼松剂量从基线至研究结论时显著下降:基线18.5(15.7)mg vs 结论时2.3(3.2)mg,P<0.01。
- 第24周与基线相比多数个体核心组指标改善,肌力改善>10%,医生总体评估改善>40%。
- RCI被认为安全可耐受,无患者出现明显体重增加、血红蛋白A1c升高或库欣样特征。
关键数值与推荐
- 纳入标准包括难治性疾病(定义为糖皮质激素和/或≥1种免疫抑制剂治疗失败)以及活动性疾病(定义为明显肌无力及>2项其他异常核心组指标,或皮肤10 cm视觉模拟量表评分≥3 cm且至少3项其他异常核心组指标)。
- 主要终点为国际肌炎评估与临床研究定义的改善;次要终点包括安全性、耐受性、减少激素用量以及2016年美国风湿病学会(ACR)/欧洲抗风湿病联盟(EULAR)肌炎应答标准。
- 所有患者接受RCI 80单位皮下注射、每周两次、共24周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To evaluate the efficacy, safety, tolerability and steroid-sparing effect of repository corticotropin injection (RCI), in an open-label clinical trial, in refractory adult polymyositis (PM) and dermatomyositis (DM). METHODS: Adults with refractory PM and DM were enrolled by two centres. Inclusion criteria included refractory disease defined as failing glucocorticoid and/or ≥1 immunosuppressive agent, as well as active disease defined as significant muscle weakness and >2 additional abnormal core set measures (CSMs) or a cutaneous 10 cm Visual Analogue Scale score of ≥3 cm and at least three other abnormal CSMs. All patients received RCI of 80 units subcutaneously twice weekly for 24 weeks. The primary end point for the trial was the International Myositis Assessment and Clinical Studies definition of improvement. Secondary end points included safety, tolerability, steroid-sparing as well as the 2016 American College of Rheumatology (ACR)/European League Against Rheumatism myositis response criteria (EULAR) RESULTS: Ten of the 11 enrolled subjects (6 DM, 4 PM) completed the study. Seven of 10 met the primary end point of efficacy at a median of 8 weeks. There was a significant decrease in prednisone dose from baseline to conclusion (18.5 (15.7) vs 2.3 (3.2); P<0.01). Most individual CSMs improved at week 24 compared with the baseline, with the muscle strength improving by >10% and the physician global by >40%. RCI was considered safe and tolerable. No patient developed significant weight gain or an increase of haemoglobin A1c or cushingoid features. CONCLUSION: Treatment with RCI was effective in 70% of patients, safe and tolerable, and led to a steroid dose reduction in patients with adult myositis refractory to glucocorticoid and traditional immunosuppressive drugs. TRIAL REGISTRATION NUMBER: NCT01906372; Results.
引用
- Aggarwal R, Marder G, Koontz DC, et al. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann Rheum Dis. 2017. PMID: 29237618. doi:10.1136/annrheumdis-2017-212047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。